| Cat.No. | Name | Information |
|---|---|---|
| M59308 | Rovalpituzumab-MMAE | Rovalpituzumab-MMAE is an antibody-drug conjugate (ADC) targeting DLL3. Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab has activity against small cell lung cancer (SCLC). |
| M59304 | Girentuximab-MMAE | Girentuximab-MMAE is an antibody-drug conjugate (ADC) targeting Carbonic anhydrase 9. Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX). |
| M59303 | Talacotuzumab-MMAE | Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody. |
| M59291 | Clivatuzumab-MMAE | Clivatuzumab-MMAE is an antibody-drug conjugate (ADC), Clivatuzumab is targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. |
| M59283 | Carotuximab-MMAE | Carotuximab-MMAE is an antibody-drug conjugate (ADC) targeting Endoglin / CD105. Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. |
| M59280 | Murlentamab-MMAE | Murlentamab-MMAE is an antibody-drug conjugate (ADC) targeting AMHR2. |
| M59153 | Ensituximab-MMAE | Ensituximab-MMAE is an antibody-drug conjugate (ADC) targeting a variant of MUC5AC. |
| M59146 | Ecromeximab-MMAE | Ecromeximab-MMAE is an antibody-drug conjugate (ADC) targeting ganglioside GD3. |
| M59136 | Inotuzumab MMAE | Inotuzumab MMAE is an anti-CD22 antibody-drug conjugate (ADC). |
| M59105 | Ulocuplumab-MMAE | Ulocuplumab-MMAE is an antibody-drug conjugate (ADC). |
| M59100 | Lorvotuzumab-MMAE | Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC). |
| M59093 | Anetumab-MMAE | Anetumab-MMAE is an antibody-drug conjugate (ADC). |
| M59087 | Praluzatamab-MMAE | Praluzatamab-MMAE is an antibody-drug conjugate (ADC). |
| M59076 | Oregovomab-MMAE | Oregovomab-MMAE is an antibody-drug conjugate (ADC). |
| M59075 | Patritumab-MMAE | Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE. |
| M59070 | Depatuxizumab mafodotin | Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII. |
| M59066 | Ozuriftamab vedotin | Ozuriftamab vedotin (BA3021) is an antibody-drug conjugate (ADC), it is composed of receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab and VcMMAE. |
| M58984 | Glembatumumab vedotin | Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects. |
| M58983 | Denintuzumab-MMAF | Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. |
| M58982 | Enapotamab vedotin | Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
